Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233088 | 0.86 | KCNMA1 (0.62) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL16583563 | 0.80 | TDP1 (0.60) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL16583251 | 0.80 | TDP1 (0.65) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL792691 | 0.80 | LMNA (0.45) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL5233828 | 0.78 | KCNMA1 (0.47) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL2034927 | 0.78 | TDP1 (0.49) | TDP1L3MBTL1SMN1; SMN2LMNATSHR | |
| SCHEMBL5237413 | 0.77 | ALDH1A1 (0.53) | TDP1KCNMA1SMN1; SMN2LMNACRHBP | |
| SCHEMBL4725431 | 0.76 | TDP1 (0.46) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL4725420 | 0.76 | TDP1 (0.46) | TDP1L3MBTL1KCNMA1SMN1; SMN2LMNA | |
| SCHEMBL5234546 | 0.76 | KCNMA1 (0.44) | KCNMA1SMN1; SMN2LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3153514-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-1761540-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2612862-B1 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2016-03-17 | — | — | US | disclosed |
| US-9149477-B2 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130116266-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8207153-B2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| CN-102229609-A | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP | 2011-11-02 | — | — | CN | disclosed |
| US-7932260-B2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| CN-101031569-A | Quinazolinones as human phosphatidylinositol 3-kinase delta inhibitors | ICOS CORP (US) | 2007-09-05 | — | — | CN | disclosed |
| WO-2005113554-A2 | METHOD OF PREPARING 3-PHENYL-2-[9H-PURIN-6-YLAMINO)-METHYL]-3H-QUINAZOLIN-4-ONE AND SUBSTITUTED AND RELATED COMPOUNDS | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256167-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | TDP1 1449/4885L3MBTL1 2857/4885KCNMA1 1544/4885 |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | TDP1 1449/4885L3MBTL1 2857/4885KCNMA1 1544/4885 |
| US-20100256168-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | TDP1 1449/4885L3MBTL1 2857/4885KCNMA1 1544/4885 |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | TDP1 1242/4885L3MBTL1 3958/4885KCNMA1 1404/4885 |
| US-20130116266-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PI4KA, PI4KB, PIK3CD | TDP1 840/4885L3MBTL1 1333/4885KCNMA1 951/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | TDP1 1449/4885L3MBTL1 2857/4885KCNMA1 1544/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | TDP1 1449/4885L3MBTL1 2857/4885KCNMA1 1544/4885 |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | PIK3CD, PIK3CA, PIK3CB | TDP1 619/4885L3MBTL1 3859/4885KCNMA1 1032/4885 |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | TDP1 1449/4885L3MBTL1 2857/4885KCNMA1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.